Gemina Laboratories Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Rob Greene
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.2yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Oct 31 2025 | n/a | n/a | -CA$3m |
| Jul 31 2025 | n/a | n/a | -CA$3m |
| Apr 30 2025 | n/a | n/a | -CA$4m |
| Jan 31 2025 | n/a | n/a | -CA$4m |
| Oct 31 2024 | n/a | n/a | -CA$3m |
| Jul 31 2024 | n/a | n/a | -CA$4m |
| Apr 30 2024 | n/a | n/a | -CA$4m |
| Jan 31 2024 | n/a | n/a | -CA$5m |
| Oct 31 2023 | n/a | n/a | -CA$6m |
| Jul 31 2023 | n/a | n/a | -CA$6m |
| Apr 30 2023 | n/a | n/a | -CA$7m |
| Jan 31 2023 | CA$156k | CA$156k | -CA$6m |
| Oct 31 2022 | n/a | n/a | -CA$5m |
| Jul 31 2022 | n/a | n/a | -CA$6m |
| Apr 30 2022 | n/a | n/a | -CA$4m |
| Jan 31 2022 | CA$180k | CA$180k | -CA$5m |
| Oct 31 2021 | n/a | n/a | -CA$4m |
| Jan 31 2021 | CA$40k | CA$40k | -CA$1m |
Compensation vs Market: Insufficient data to establish whether Rob's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
CEO
Rob Greene
Dr. Robert Crandall Greene, also known as Rob, is Chief Executive Officer from 2025 & Director of Gemina Laboratories Ltd since January 31, 2021 and was it's Chief Technology Officer since September 1, 202...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.2yrs | CA$155.66k | no data | |
| Chair of Clinical Advisory Board | 3.3yrs | no data | no data | |
| Independent Chairman | 5.2yrs | CA$107.25k | no data | |
| Independent Director | 5yrs | CA$10.00k | no data |
Experienced Board: GLAB.F's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/29 06:17 |
| End of Day Share Price | 2025/12/31 00:00 |
| Earnings | 2025/10/31 |
| Annual Earnings | 2025/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gemina Laboratories Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.